Collaborations

[Abstract] Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma

Background: Pancreatic cancers (PDACs) with BRCA1/2 pathogenic variants (PVs) are prognostically favorable and predict response to …

Ryan Hood, Srishti Rathore, Nicholas J. Seewald, Kim Anna Reiss

[Abstract] Interaction of BRCA1 vs BRCA2 pathogenic variants with primary tumor location in pancreatic cancer

Background: BRCA1/2 germline or somatic pathogenic variants (PVs) are found in 5-10% of pancreatic adenocarcinoma (PDAC) patients. …

Ryan Hood, Nicholas J. Seewald, Srishti Rathore, Kim Anna Reiss

[Abstract] CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Background: Exemestane is a second generation steroidal aromatase inhibitor (AI) used for the treatment of estrogen receptor (ER) …

Daniel L. Hertz, Kelley M. Kidwell, Nicholas J. Seewald, Christina L. Gersch, Zeruesenay Desta, David A. Flockhart, Ana-Maria Storniolo, Vered Stearns, Todd C. Skaar, Daniel F. Hayes, N. Lynn Henry, James M. Rae"

[Abstract] Crossover from One Aromatase Inhibitor (AI) to Another in the Exemestane and Letrozole Pharmacogenetics (ELPh) Trial

Background: Tolerance of AI therapy can be poor due to treatment-emergent toxicities and can lead to early discontinuation …

Kunal C. Kadakia, Kelley M. Kidwell, Nicholas J. Seewald, Claire Frances Snyder, David A. Flockhart, Janet S. Carpenter, Julie L. Otte, Daniel F. Hayes, Anna Maria Storniolo, Vered Sterns, Norah Lynn Henry

[Abstract] Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy

ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I

Kunal C. Kadakia, Claire Frances Snyder, Kelley M Kidwell, Nicholas J. Seewald, Anna Maria Storniolo, David A. Flockhart, Janet S. Carpenter, Daniel F. Hayes, Vered Stearns, Norah Lynn Henry

[Abstract] Primary CNS Lymphoma; A Review of the University of Michigan Experience 2004-2013

Background: Evidence supports high dose methotrexate (HD-MTX), rituximab, and cytarabine treatment for newly diagnosed primary CNS …

Aaron G. Mammoser, Shaio-Pei S. Weathers, Nicholas J. Seewald, Jeremy M. G. Taylor, Larry Junck